{"id":568863,"date":"2021-10-13T16:06:01","date_gmt":"2021-10-13T16:06:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=568863"},"modified":"2021-10-13T16:06:01","modified_gmt":"2021-10-13T16:06:01","slug":"irritable-bowel-syndrome-epidemiology-forecast-report-2030-irritable-bowel-syndrome-epidemiology-analysis-2030-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/irritable-bowel-syndrome-epidemiology-forecast-report-2030-irritable-bowel-syndrome-epidemiology-analysis-2030-delveinsight_568863.html","title":{"rendered":"Irritable Bowel Syndrome Epidemiology Forecast Report 2030 | Irritable Bowel Syndrome Epidemiology Analysis 2030 | DelveInsight"},"content":{"rendered":"
\n
\"Irritable<\/a><\/div>\n
\n
DelveInsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n
DelveInsight’s ‘Irritable Bowel Syndrome (IBS) – Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted Irritable Bowel Syndrome (IBS) epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.<\/div>\n

DelveInsight launched a new report on Irritable Bowel Syndrome Epidemiology Forecast, 2030.<\/a><\/strong><\/p>\n

DelveInsight’s ‘Irritable Bowel Syndrome Epidemiology Forecast to 2030‘<\/a> <\/strong>report delivers an in-depth understanding of the disease, historical and forecasted Irritable Bowel Syndrome epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.<\/p>\n

\"\"<\/p>\n

Irritable bowel syndrome is one of the most commonly diagnosed gastrointestinal diseases. Irritable Bowel Syndrome, in the absence of any other causative disease, is defined as the presence of abdominal pain or discomfort with altered bowel habits. The etiology of Irritable bowel syndrome is broad and not clearly understood. However, the pathophysiology of Irritable Bowel Syndrome is broad and includes abnormalities involving motility, visceral sensation, brain-gut interaction, and psychosocial distress. Irritable Bowel Syndrome typically consists of abdominal pain or discomfort, altered bowel habits along with either constipation, diarrhea, or both. Other complaints in patients with Irritable Bowel Syndrome include bloating, distention, symptoms brought on my food intake, and a change in pain location, and stool pattern with time. <\/p>\n

Some of the key highlights from the Irritable Bowel Syndrome Epidemiology Report:<\/a><\/strong><\/p>\n

    \n
  1. \n

    Irritable bowel syndrome can be a very disabling syndrome for patients, and it has been shown to be a very common reason for seeking medical attention. Nearly 12% of patients seek medical care in primary care practices for Irritable Bowel Syndrome-related complaints. Studies have demonstrated that the prevalence of Irritable Bowel Syndrome ranges between 10-15%, however, the majority of these patients do not seek medical care. <\/p>\n<\/li>\n

  2. \n

    According to Oka et al., 2020, the systematic review and meta-analysis showed a  global prevalence of  Irritable Bowel Syndrome of  9·2%  when the  Rome III criteria were used, and 3·8% with the Rome IV criteria.  Irritable Bowel Syndrome prevalence varied,  considerably in some instances, according to country, whether diagnostic criteria were applied strictly or approximated,  and the method used to collect symptom data in individual studies.<\/p>\n<\/li>\n<\/ol>\n

    Visit for more @ Irritable Bowel Syndrome Epidemiology Insights<\/a><\/strong><\/p>\n

    Scope of the Irritable Bowel Syndrome Epidemiology report:<\/strong><\/p>\n

      \n
    1. \n

      The Irritable Bowel Syndrome report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis, and treatment patterns<\/p>\n<\/li>\n

    2. \n

      The Irritable Bowel Syndrome Epidemiology Report and Model provide an overview of the risk factors and global trends of Irritable Bowel Syndrome in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan)<\/p>\n<\/li>\n

    3. \n

      The report provides insight into the historical and forecasted patient pool of Irritable Bowel Syndrome in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan<\/p>\n<\/li>\n

    4. \n

      The report helps to recognize the growth opportunities in the 7MM concerning the patient population<\/p>\n<\/li>\n

    5. \n

      The report assesses the disease risk and burden and highlights the unmet needs of Irritable Bowel Syndrome<\/p>\n<\/li>\n

    6. \n

      The report provides the segmentation of the Irritable Bowel Syndrome epidemiology<\/p>\n<\/li>\n<\/ol>\n

      Table of Contents:<\/strong><\/p>\n

      1. Key Insights<\/p>\n

      2. Executive Summary of Irritable Bowel Syndrome<\/p>\n

      3. Irritable Bowel Syndrome Epidemiology Overview at a Glance<\/p>\n

      4. Irritable Bowel Syndrome: Disease Background and Overview<\/p>\n

      5. Epidemiology and Patient Population<\/p>\n

      6. Case Reports<\/p>\n

      7. Country Wise-Epidemiology of Irritable Bowel Syndrome <\/p>\n

      8. Appendix<\/p>\n

      9. DelveInsight Capabilities<\/p>\n

      10. Disclaimer<\/p>\n

      11. About DelveInsight<\/p>\n

      Read more on Irritable Bowel Syndrome Epidemiological Insights<\/a><\/strong><\/p>\n

      Media Contact<\/span>
      Company Name:<\/strong>       DelveInsight Business Research LLP<\/a>
      Contact Person:<\/strong> Kritika Rehani
      Email:<\/strong>       Send Email<\/a>
      Phone:<\/strong> 9193216187
      Address:<\/strong>304 S. Jones Blvd #2432
      City:<\/strong> Las Vegas
      State:<\/strong> Nevada
      Country:<\/strong> United States
      Website:<\/strong>       https:\/\/www.delveinsight.com\/<\/a><\/p>\n

      <\/object>\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

      DelveInsight Business Research LLP DelveInsight’s ‘Irritable Bowel Syndrome (IBS) – Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted Irritable Bowel Syndrome (IBS) epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,435,405,406,404],"tags":[],"class_list":["post-568863","post","type-post","status-publish","format-standard","hentry","category-Business","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/568863","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=568863"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/568863\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=568863"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=568863"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=568863"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}